Plain-English translation of NCT05578053 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →This is a real-world study of , a medication being used to treat advanced breast cancer that is hormone receptor-positive (meaning the cancer grows in response to hormones). The study is not testing whether works—it's already being used in practice—but rather watching how it performs in everyday clinical care and how safe it is for patients like you.
While this medication is already approved and in use, doctors want to better understand how it works in real patients across different hospitals and treatment settings, rather than just in controlled clinical trials. This helps them learn which patients benefit most and what side effects to watch for.
You likely qualify if…
You likely don't qualify if…
You will receive along with other standard breast cancer treatments as your doctor recommends—there are no restrictions on how the medication is combined with other therapies. During the study, you'll have routine imaging scans and safety blood tests according to your normal cancer care schedule. The research team will track how well the treatment is working and watch for any side effects, but you'll follow your doctor's usual visiting schedule.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China
Sponsor
Hebei Medical University Fourth Hospital
Enrollment target
~420 participants
Started
September 2024
Primary completion
December 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
cuizhi Geng Cuizhi Geng, archiater
Hebei Medical University Fourth Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.